Clene’s FDA up­date; JCR ends ties with Take­da, part­ners with As­traZeneca; Gilead ups stake in Hookipa

Plus, news on Lyn­dra Ther­a­peu­tics, Hadean Cap­i­tal, Barinthus Bio, Shat­tuck Labs and In­ven­ti­va.

Clene Nanomed­i­cine’s road­block: The com­pa­ny, which is de­vel­op­ing a gold nanocrys­tal-based drug to treat ALS called CNM-Au8, met with the FDA to dis­cuss the pos­si­bil­i­ty of an ac­cel­er­at­ed ap­proval us­ing bio­mark­er da­ta for neu­ro­fil­a­ment light chain — the same bio­mark­er for which Bio­gen’s Qal­sody won ap­proval ear­li­er this year. But the reg­u­la­tor told Clene that the da­ta from stud­ies com­plet­ed so far are “in­suf­fi­cient to sup­port ac­cel­er­at­ed ap­proval at this time,” per a Clene press re­lease. Clene did not ex­pand on the FDA’s rea­sons, and it’s un­clear if the agency will re­quire Clene to con­duct an ad­di­tion­al study be­fore sub­mit­ting for ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER